Ivana K. Kim, MD, Associate Professor of Ophthalmology at Harvard Medical School and Director of the Macular Degeneration Unit and Co-Director of the Ocular Melanoma Center, was selected to present the Paul Henkind Memorial Lecture at the Macula Society 2022 annual meeting in June.... Read more about Ivana Kim, MD, to Present Paul Henkind Memorial Lecture
This year's Iraty Award for Research in Retinal Diseases honors Petr Baranov, PhD, a scientist at Schepens Eye Research Institute of Mass. Eye and Ear and Assistant Professor of Ophthalmology...
The Atlantic Coast Retina Club (ACRC) Meeting and Macula 2019 Conference was held at Mass. Eye and Ear and the Seaport Hotel on January 10-12.... Read more about ACRC/Macula 2019 a Success
Boston, Mass. — Massachusetts Eye and Ear made medical history on Tuesday by performing the first post-FDA approval gene therapy for patients with a form of inherited blindness. The occasion marks the beginning of a new era in medicine, as it is the first time any FDA-approved gene therapy has been given to a patient for any inherited disease.
The treatment, commercially identified as Luxturna, was developed by Spark Therapeutics and ...
The VitreoRetinal Surgery Foundation recognized four trainees with research awards and fellowships, enabling them to pursue research investigations at Mass. Eye and Ear and Schepens Eye Research Institute of Mass. Eye and Ear. The VitreoRetinal Surgery Foundation (VRSF) strives to promote education and research related to retinal and macular diseases. They support research by funding awards for young investigators with a potential for a career devoted to retinal disease and research. The VRSF has established a competitive Research Award/Fellowship to encourage young physicians to...
Ocugen, Inc. has obtained an exclusive worldwide license to develop and commercialize future ophthalmology products based on groundbreaking technology developed by Neena Haider, PhD, Associate Professor of Ophthalmology....